appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Dr Reddy's Laboratories Ltd
DRREDDY
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.
Brands
Brands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Lupin Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 2.10%
Recent NewsAll news
Market Trading Guide: Tata Power, Dr Reddy’s Labs among 6 stock recommendations for Friday - Stock Ideas
1 month ago•Economic Times
Nestle India Invests Rs 705 Crore In JV With Dr Reddy’s Labs
1 month ago•Bloomberg Quint
D-St cheers Fed’s dovish tone: Nifty surges past 25K milestone, Sensex sets new record
1 month ago•Economic Times
After $4 billion Infosys demand, India may target other IT majors, source says
1 month ago•Economic Times
Shifting Gears: Dr Reddy’s scaling up JVs, inorganic growth to add value, expand market reach
1 month ago•The Hindu Businessline
Q1FY25 Earnings Update: Dr Reddy Laboratories Profit Dips Marginally To ₹1,392 Cr; Revenue At ₹7,673 Cr
1 month ago•Free Press Journal
Dr Reddy’s Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%
1 month ago•Business Standard
Dr Reddy’s Laboratories board announces 1:5 stock split
1 month ago•Economic Times
Dr Reddy’s Laboratories consolidated net profit declines 0.90% in the June 2024 quarter
1 month ago•Business Standard
ICICI Bank, Dr Reddy’s Labs, REC, IDFC First Bank Q1 Results Today — Earnings Estimates
1 month ago•Bloomberg Quint
Recent EventsAll events
Shareholders meeting
Dr. Reddy's Laboratories Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download
Dr. Reddy's Laboratories Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download
Cash Dividend
Final • Div/Share: ₹ 40
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant